NCT02682680View on ClinicalTrials.gov

Randomized Trial Comparing Colesevelam vs. Ezetimibe

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 11, 2016

Primary Completion Date

May 25, 2017

Study Completion Date

May 25, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Colesevelam

Colesevelam 3.75 g daily for 24 weeks

DRUG

Ezetimibe

Ezetimibe 10 mg daily for 24 weeks

Trial Locations (9)

Unknown

LMC Calgary, Calgary

LMC Barrie, Barrie

LMC Etobicoke, Etobicoke

LMC Markham, Markham

LMC Oakville, Oakville

LMC Thornhill, Thornhill

LMC Bayview, Toronto

L6S 0C9

LMC Brampton, Brampton

M9W 4L6

Manna Toronto, Toronto

All Listed Sponsors
collaborator

Bausch Health Americas, Inc.

INDUSTRY

lead

LMC Diabetes & Endocrinology Ltd.

OTHER

NCT02682680 - Randomized Trial Comparing Colesevelam vs. Ezetimibe | Biotech Hunter | Biotech Hunter